Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Assets (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Current Assets for 7 consecutive years, with $666.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 3.33% to $666.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $666.7 million through Dec 2025, down 3.33% year-over-year, with the annual reading at $666.7 million for FY2025, 3.33% down from the prior year.
  • Current Assets hit $666.7 million in Q4 2025 for IDEAYA Biosciences, down from $802.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $932.2 million in Q3 2024 to a low of $251.0 million in Q4 2021.
  • Historically, Current Assets has averaged $508.4 million across 5 years, with a median of $492.0 million in 2023.
  • Biggest five-year swings in Current Assets: soared 244.45% in 2021 and later decreased 16.91% in 2022.
  • Year by year, Current Assets stood at $251.0 million in 2021, then skyrocketed by 47.59% to $370.5 million in 2022, then skyrocketed by 43.78% to $532.6 million in 2023, then grew by 29.49% to $689.7 million in 2024, then fell by 3.33% to $666.7 million in 2025.
  • Business Quant data shows Current Assets for IDYA at $666.7 million in Q4 2025, $802.7 million in Q3 2025, and $685.6 million in Q2 2025.